Zydus Lifesciences

    ZYDUSLIFE
    Pharma
    ₹1,129.40
    Price as of 25 Oct 2026, 10:28 pm IST

    Market cap ₹1.13 L Cr

    P/E
    25.17
    Day range
    ₹1,118.90 – ₹1,143.50
    52-week range
    ₹835.50 – ₹1,232.10
    Volume
    15.04 L
    Open
    ₹1,138.00
    Prev close
    ₹1,135.00

    Latest results · Q1 FY27(consolidated)Revenue ₹8,017 Cr+22.0%Profit ₹990 Cr-34.9%Margin 12.4%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    ZYDUSLIFE in NSE indices and F&O

    F&O margin for one lot of ZYDUSLIFE (900 shares)

    Research profile

    Composite 67 / 100

    Factor percentiles

    Value47
    Quality51
    Momentum78
    Low volatility92

    Derived metrics

    Earn. yield
    4.0%
    Graham no.
    ₹543.98
    vs Graham
    -51.8%
    ROE ÷ P/B
    4.8%
    12-1 mom.
    +16.6%
    Return / vol
    0.60
    Magic Formula
    #162
    Piotroski
    1/6
    FCF yield
    -0.5%
    PEG
    3.22

    Appears in 8 scans

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 67 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.19 L Cr34.685.0214.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.38 L Cr81.2114.5216.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.72 L Cr76.439.3726.8%15.0%33.0%0.77+50.8%
    Zydus LifesciencesZYDUSLIFE₹1.13 L Cr25.174.2020.1%21.0%24.0%0.46+22.0%
    Apollo HospitalsAPOLLOHOSP₹1.11 L Cr53.1911.5422.6%17.0%16.0%0.90+20.6%
    CiplaCIPLA₹1.08 L Cr32.093.1211.8%15.0%17.0%0.02+2.3%
    Laurus LabsLAURUSLABS₹1.06 L Cr97.3820.0618.2%18.0%32.0%0.48+29.0%
    Dr. Reddy's LabsDRREDDY₹1.02 L Cr36.602.7311.6%13.0%11.0%0.20-5.5%
    Sector median₹23,579 Cr41.615.6015.1%17.0%25.0%0.16+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 6d ago

    Headlines about Zydus Lifesciences from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.

    Key metrics

    P/E (TTM)
    23.1
    EPS (TTM)
    ₹44.87
    Price / Book
    4.20
    ROE (FY26)
    20.1%
    ROCE (latest year)
    21%
    Dividend yield
    0.09%

    Moving averages (NSE)

    20-day
    ₹1,148.98
    Price below
    50-day
    ₹1,145.07
    Price below
    200-day
    ₹1,025.16
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +16.3%
    Profit 3Y CAGR
    +34.8%
    Revenue YoY (Jun 2026)
    +22.0%
    Profit YoY (Jun 2026)
    -34.9%
    Operating margin
    24.0%
    Net margin
    12.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Jun 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-10K Cr-5K Cr0 Cr5K Cr10K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr10K Cr20K Cr30K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26₹0₹5₹10₹15

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales4,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,5878,017
    Expenses3,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,0336,088
    Operating Profit1,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,5541,929
    OPM %26%24%29%34%28%26%33%32%33%26%34%24%
    Other Income5360160636857-1391557526-26388
    Interest920353225327785101130123156
    Depreciation184195205215234229238238302360508555
    Profit before tax1,0069471,5501,9001,2711,1841,6721,9211,6871,3531,6601,307
    Tax %22%23%21%23%29%15%25%23%27%29%19%27%
    Net Profit8037901,2461,4829201,0261,2441,5211,2391,0231,341990
    EPS in Rs₹7.91₹7.80₹11.75₹14.11₹9.06₹10.17₹11.64₹14.58₹12.51₹10.36₹12.65₹9.42

    From company filings, updated 25 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days73

    -3 days since Mar 2021

    Inventory Days282

    +55 days since Mar 2021

    Days Payable142

    -13 days since Mar 2021

    Cash Conversion Cycle212

    +64 days since Mar 2021

    Working Capital Days-40

    -34 days since Mar 2021

    Strengths, risks & growth

    In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

    Strengths

    • Company has delivered good profit growth of 18.8% CAGR over last 5 years

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    +11%
    5 Years
    +12%
    3 Years
    +16%
    TTM
    +21%

    Compounded Profit Growth

    10 Years
    +11%
    5 Years
    +19%
    3 Years
    +32%
    TTM
    +5%

    Stock Price CAGR

    10 Years
    +11%
    5 Years
    +18%
    3 Years
    +25%
    1 Year
    +12%

    Return on Equity

    10 Years
    +20%
    5 Years
    +21%
    3 Years
    +21%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter75.00%75.00%75.02%75.01%-0.01 pp
    FII7.06%6.95%6.89%7.05%+0.16 pp
    DII11.08%11.20%11.27%11.28%+0.01 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public6.86%6.86%6.83%6.66%-0.17 pp

    Filed with NSE for Sept 2026: promoters 75.01%, public 24.99% · XBRL filing

    Analysts & fund holdings

    58%
    58% recommend buy
    26 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E25.2 vs 44.2
    Sector P/B5.54
    Beta0.60

    Who holds the shares, quarter by quarter

    Mutual funds 6.88% (+1.76 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters75.0%
    • Foreign institutions7.0%
    • Mutual funds6.9%
    • Insurance4.2%
    • Other domestic institutions0.2%
    • Retail4.6%
    • Others2.1%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Parag Parikh Flexi Cap Fund2.00%1.54%+0.05 pp
    Kotak Flexi Cap Fund1.08%2.28%+0.20 pp
    HSBC Midcap Fund0.42%2.82%+2.82 pp
    Quant Mid Cap Fund0.38%5.57%+5.57 pp
    Bandhan Large & Mid Cap Fund0.31%1.66%+1.04 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 274 daily sessions to 22 Oct 2026.

    Computed

    Risk

    Volatility (1Y)
    23.4%
    Downside volatility
    22.3%
    Worst 5% of days
    2.5%
    Average of that tail
    3.3%
    Max drawdown (1Y)
    17.9%
    Below its peak
    6.6%

    Against the market

    Beta vs Nifty 50
    0.66
    Correlation
    0.38
    Relative strength (3M)
    +6.2%
    ATR (14)
    2.7%

    Return

    Return 1M
    -2.2%
    Return 3M
    +0.8%
    Return 6M
    +22.2%
    Return 1Y
    +14.0%
    vs 200-day average
    +10.7%

    Momentum

    RSI (14)
    48.8
    MACD histogram
    -2.81
    Stochastic %K
    51.7
    ADX (14)
    10.8
    +DI / −DI
    17.7 / 19.1
    Money flow index
    32.4

    Participation

    Delivery (20d avg)
    52.0%
    vs its 60-day baseline
    -0.4 pts
    Volume vs 20-day
    -0.2σ
    Close vs day's VWAP
    +0.7%
    52-week position
    77 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    1 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    -₹555 Cr
    FCF yield
    -0.5%
    Cash conversion
    0.41
    Accruals ratio
    0.057
    Net debt
    ₹11,641 Cr
    Net debt / equity
    0.43
    EV / sales
    4.35
    PEG
    3.22
    Capex intensity
    9.8%
    Revenue CAGR
    16.2%
    Profit CAGR
    7.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹9.6 L
    2 buys · ₹9.6 L
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Prashant Babubhai Patel
    Promoter Group · Others
    		Buy32,577₹024 Aug 2026
    Jasodaben Babubhai Patel
    Promoter Group · Market Purchase
    		Buy1,000₹9.6 L17 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      24 Jul 2026
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      29 May 2026
      ex-date
    • dividend
      ₹11.00

      Dividend - Rs 11 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      26 Jul 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      23 Feb 2024
      ex-date
    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      28 Jul 2023
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      28 Jul 2022
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      1 Jun 2022
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      28 Jul 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      12 Aug 2020
      ex-date
    • dividend
      ₹3.50

      Interim Dividend - Rs 3.50 Per Share

      23 Mar 2020
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      25 Jul 2019
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend- Rs 3.50 Per Share (Purpose Revised)

      31 Jul 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Jul 2017
      ex-date
    • dividend
      ₹3.20

      Interim Dividend Rs 3.20 Per Share (Purpose Revised)

      16 Mar 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jul 2016
      ex-date
    • dividend
      ₹3.20

      Interim Dividend - Rs 3.20/- Per Share

      17 Mar 2016
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share

      6 Oct 2015
      ex-date
    • dividend
      ₹12.00

      Annual General Meeting/Dividend - Rs 12/- Per Share

      30 Jul 2015
      ex-date
    • dividend
      ₹9.00

      Annual General Meeting / Dividend - Rs 9/- Per Share

      17 Jul 2014
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Q2 FY27 post results earning call details

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zylidac Bio and Prolific Machines Partner to Scale Prolific's Next-Generation Biologics Manufacturing Platform to GMP Production.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30, 2026.

    Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve unaudited financial results ....

    Company Update
    ESG Rating
    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    USFDA Inspection

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus, MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Updates on Joint Venture

    Extension of date of closing

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    USFDA inspection concludes at Zydus' manufacturing plant at SEZ II, Ahmedabad.

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Trading Window Closure

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus' USA Office with nil observations.

    Filed with BSE (scrip 532321); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 12 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Zydus Lifesciences: common questions

    Answered from the figures on this page.

    Zydus Lifesciences last traded at ₹1,129.40 (NSE, as of 25 Oct 2026). The last session moved it down 0.49%.

    Zydus Lifesciences is valued at about ₹1.13 lakh crore (NSE, as of 25 Oct 2026).

    Zydus Lifesciences trades at a price-to-earnings ratio of 25.17 (NSE, as of 25 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Zydus Lifesciences has traded between ₹835.50 and ₹1,232.10 over the past 52 weeks, to 25 Oct 2026. It is currently 74% of the way up that range.

    Zydus Lifesciences (ZYDUSLIFE) is classified under Pharma on this site's screener.